KRAS-mediated aberrant activation of the MEK and ERK signaling pathways promotes abnormal cell differentiation and sustained growth, thereby driving the development and progression of pancreatic cancer.3 However, various drugs targeting KRAS mutations or its downstream signaling pathways do not improve therapeutic efficacy of pancreatic cancer in the clinic. Here, KRAS is linked to familial pancreatic carcinoma.